Update on and Future Directions for Use of Anti-SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19.

César Boggiano, Robert W Eisinger, Andrea M Lerner, James M Anderson, Janet Woodcock, Anthony S Fauci, Francis S Collins

Annals of internal medicine 2022 Jan

filter terms:

As the fourth wave of the SARS-CoV-2 pandemic encircles the globe, there remains an urgent challenge to identify safe and effective treatment and prevention strategies that can be implemented in a range of health care and clinical settings. Substantial advances have been made in the use of anti-SARS-CoV-2 antibodies to mitigate the morbidity and mortality associated with COVID-19. On 15 June 2021, the National Institutes of Health, in collaboration with the U.S. Food and Drug Administration, convened a virtual summit to summarize existing knowledge on anti-SARS-CoV-2 antibodies and to identify key unanswered scientific questions to further catalyze the clinical development and implementation of antibodies.

Citation

César Boggiano, Robert W Eisinger, Andrea M Lerner, James M Anderson, Janet Woodcock, Anthony S Fauci, Francis S Collins. Update on and Future Directions for Use of Anti-SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19. Annals of internal medicine. 2022 Jan;175(1):119-126